Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE The single transmembrane domain (TMD) of the human thrombopoietin receptor (TpoR/MPL), encoded by exon 10 of the MPL gene, is a hotspot for somatic mutations associated with myeloproliferative neoplasms (MPNs). 31697803 2020
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE Studies have shown that mutant calreticulin (CALR) constitutively activates the thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of myeloproliferative neoplasms (MPNs). 31462733 2020
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. 31092065 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) share similar molecular characteristics in that they frequently harbor hotspot mutations in JAK2, CALR or MPL, leading to activated JAK/STAT signaling. 31071164 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Myeloproliferative neoplasms (MPNs) are associated with somatic mutations of genes including JAK2, CALR, or MPL in hematopoietic stem cells. 31377025 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE The introduction of next-generation sequencing has broadened the genetic landscape of myeloproliferative neoplasms (MPNs) beyond JAK2, MPL, and CALR. 30594750 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Sequential genotyping for phenotype-driver mutations in JAK2 (exon 14), CALR (exon 9), and MPL (exon 10) is recommended in patients with myeloproliferative neoplasms. 31135094 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE Recent data demonstrated that the TPO receptor (MPL) is essential for the development of CALR mutant-driven Myeloproliferative Neoplasms (MPNs). 31332222 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 AlteredExpression group BEFREE Studies have previously shown that mutant calreticulin (CALR), found in a subset of patients with myeloproliferative neoplasms (MPNs), interacts with and subsequently promotes the activation of the thrombopoietin receptor (MPL). 29946189 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE Mutations in <i>CALR</i> observed in myeloproliferative neoplasms (MPN) were recently shown to be pathogenic via their interaction with MPL and the subsequent activation of the Janus Kinase - Signal Transducer and Activator of Transcription (JAK-STAT) pathway. 31810292 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Two activating mutations of MPL in triple-negative myeloproliferative neoplasms. 31294534 2019
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent mutations of driver genes including JAK2, CALR and MPL. 29306106 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Together, our findings provide additional insights into the mechanism of the pathogenic mutant CALR-MPL interaction in myeloproliferative neoplasms. 29288169 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms. 29323541 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE We describe here such an association of CALR and MPL mutations in a patient harboring the second mutation in a subclone during the phenotypic evolution of the myeloproliferative neoplasms. 28556926 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE BCR/ABL1-negative myeloproliferative neoplasms (MPNs) are characterized by recurrent mutations in JAK2, CALR, and MPL, each of which has been reported to alter JAK/STAT signaling pathways. 27258562 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE An inhibitor for the thrombopoietin receptor (TpoR) would be more specific for the treatment of myeloproliferative neoplasms (MPNs) due to constitutively active mutant TpoR compared to the current treatment approach of inhibiting Janus kinase 2 (JAK2). 29736709 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Somatic mutations in JAK2, MPL and CALR are recurrently identified in most of the cases with Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). 28411309 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE The discovery of the activating Janus kinase (JAK)2<sup>V617F</sup> mutation in 2005 in most patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in the gene encoding calreticulin (CALR) in 2013, thus providing additional mechanistic explanations for the universal activation of JAK-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011. 29277359 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE The majority of patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) harbor JAK2, CALR, or MPL mutations. 29464483 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. 28990497 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group BEFREE JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). 28828906 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 Biomarker group CTD_human Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical myeloproliferative neoplasms (MPN), characterized by specific somatic mutations in JAK2, CALR or MPL genes. 29047144 2018
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. 29042365 2017
Entrez Id: 4352
Gene Symbol: MPL
MPL
0.500 GeneticVariation group BEFREE The findings from this study support the possibility of coexisting mutations of the JAK2, CALR, and MPL genes in myeloproliferative neoplasms and suggest that CALR and MPL should be analyzed not only in JAK2-negative patients but also in low V617F mutation patients. 27855276 2017